Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 3/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936882 | 0.83 | SCN9A (0.35) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17926321 | 0.82 | SCN9A (0.35) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17936938 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17925953 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17925956 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17936851 | 0.82 | MAP4K4 (0.36) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17926275 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17926278 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17925955 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 | |
| SCHEMBL17936777 | 0.82 | SCN9A (0.34) | SCN9AMAP4K4GPR119HDAC1SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | SCN9A 4557/4885MAP4K4 2727/4885GPR119 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.